Login / Signup

Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma.

Hiroki IshiharaToshio TakagiTsunenori KondoHironori FukudaKazuhiko YoshidaJunpei IizukaKazunari Tanabe
Published in: Targeted oncology (2019)
Decreased SMM during first-line sunitinib therapy can be an effective marker of outcome prediction for mRCC.
Keyphrases
  • metastatic renal cell carcinoma
  • skeletal muscle
  • insulin resistance
  • rectal cancer
  • radical prostatectomy
  • type diabetes
  • metabolic syndrome
  • adipose tissue
  • bone marrow
  • mesenchymal stem cells
  • minimally invasive